Jain Global’s Aclaris Therapeutics ACRS Stock Holding History

Jain Global’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-65,672	Closed	-$100K	–	1145
2025 Q1	$100K	Buy	65,672 +41,212	+168%	+$87.9K	﹤0.01%	967
2024 Q4	$60.7K	Buy	+24,460	New	+$60.9K	﹤0.01%	707

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jain Global's ACRS Position: Q2 2025 in Review

Jain Global sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 65,672 shares — an estimated $100K sold.

Jain Global first reported a position in ACRS in Q4 2024 and held it in 2 quarters. The position peaked at $100K in Q1 2025. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

Jain Global reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
Jain Global sold 65,672 Aclaris Therapeutics shares in Q2 2025, an estimated $100K.
Jain Global first reported a position in Aclaris Therapeutics in Q4 2024 and held it in 2 quarters.
Jain Global's Aclaris Therapeutics position peaked at $100K in Q1 2025.
96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Jain Global's 13F filing for Q2 2025, filed 14 Aug 2025.